Deflazacort - Marathon Pharmaceuticals

Drug Profile

Deflazacort - Marathon Pharmaceuticals

Alternative Names: 21 desacetyl DFZ prodrug; DFZ; EMFLAZA; MP-104

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Marathon Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy

Most Recent Events

  • 24 Aug 2017 Marathon Pharmaceuticals completes a long-term extension phase I trial in Duchenne muscular dystrophy (In children, In adolescents) in USA (PO) (NCT02295748)
  • 08 May 2017 PTC Therapeutics plans to launch Deflazacort in USA for Duchenne muscular dystrophy
  • 20 Apr 2017 Deflazacort - Marathon Pharmaceuticals licensed to PTC Therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top